patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_267662 | REC_0012301 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 16.5 | 78 | female | 2 | 8 | 5.1 | 1 | osimertinib 80 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:59.938547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174001 | REC_0012302 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 16.6 | 73 | female | 2 | 16 | 6 | 8 | alectinib 600 mg BID | 14.5 | false | MSI-H | 2026-03-15T05:35:59.938779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528925 | REC_0012303 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 8.8 | 65 | male | 0 | 18 | 5.5 | 1 | sotorasib 960 mg daily | 5.5 | false | MSS | 2026-03-15T05:35:59.939012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616212 | REC_0012304 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 17.9 | 73 | male | 1 | 6 | 5 | 4 | osimertinib 80 mg daily | 6.3 | true | MSS | 2026-03-15T05:35:59.939248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450668 | REC_0012305 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 4.3 | 58 | male | 0 | 28 | 4 | 2 | pembrolizumab 200 mg q3w | 8.9 | false | MSS | 2026-03-15T05:35:59.939482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926264 | REC_0012306 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 36 | 8.8 | 68 | female | 1 | 13 | 5.6 | 0 | pembrolizumab 200 mg q3w | 24.1 | false | MSS | 2026-03-15T05:35:59.939712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112389 | REC_0012307 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 10.1 | 72 | female | 1 | 13 | 6.1 | 7 | entrectinib 600 mg daily | 12 | true | MSS | 2026-03-15T05:35:59.939951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982058 | REC_0012308 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 14.8 | 60 | male | 1 | 13 | 5.7 | 2 | sotorasib 960 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:59.940235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457915 | REC_0012309 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 6 | 70 | female | 2 | 23 | 4.4 | 3 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:59.940491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747191 | REC_0012310 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.6 | 79 | male | 1 | 24 | 6.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:59.940747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955531 | REC_0012311 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.8 | 80 | female | 2 | 50 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 27.9 | true | MSS | 2026-03-15T05:35:59.941010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590925 | REC_0012312 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 15.6 | 62 | female | 1 | 2 | 6.1 | 2 | osimertinib 80 mg daily | 19.7 | true | MSI-H | 2026-03-15T05:35:59.941386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971395 | REC_0012313 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 8.5 | 57 | male | 0 | 13 | 4.6 | 0 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:35:59.941650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141781 | REC_0012314 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 16.6 | 56 | male | 0 | 9 | 4.9 | 5 | osimertinib 80 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:35:59.941900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566823 | REC_0012315 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 10 | 58 | male | 1 | 7 | 6 | 3 | osimertinib 80 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:35:59.942150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506049 | REC_0012316 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.2 | 50 | female | 0 | 39 | 3.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:35:59.942381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536063 | REC_0012317 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 10 | 12.3 | 64 | male | 1 | 11 | 5.6 | 6 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:59.942620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971437 | REC_0012318 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 4.8 | 72 | male | 2 | 41 | 4.8 | 1 | pembrolizumab 200 mg q3w | 21.4 | false | MSS | 2026-03-15T05:35:59.942854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227024 | REC_0012319 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 17.6 | 58 | female | 0 | 12 | 5 | 2 | sotorasib 960 mg daily | 22.8 | true | MSS | 2026-03-15T05:35:59.943090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778109 | REC_0012320 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 2.1 | 76 | female | 1 | 27 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:59.943321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763621 | REC_0012321 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 17.2 | 64 | male | 0 | 12 | 5.5 | 5 | entrectinib 600 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:35:59.943557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138995 | REC_0012322 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 16 | 65 | male | 1 | 0 | 6.1 | 1 | entrectinib 600 mg daily | 24.9 | false | MSI-H | 2026-03-15T05:35:59.943793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757297 | REC_0012323 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 3.8 | 65 | female | 0 | 21 | 6.2 | 2 | entrectinib 600 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:59.944023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501651 | REC_0012324 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 14.8 | 55 | female | 0 | 15 | 6.1 | 2 | alectinib 600 mg BID | 13.8 | false | MSI-H | 2026-03-15T05:35:59.944305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406471 | REC_0012325 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.3 | 71 | female | 2 | 84 | 3.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.6 | true | MSS | 2026-03-15T05:35:59.944615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785490 | REC_0012326 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14.2 | 78 | female | 2 | 12 | 5.5 | 6 | sotorasib 960 mg daily | 6 | false | MSI-H | 2026-03-15T05:35:59.944852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559912 | REC_0012327 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 6.8 | 66 | female | 1 | 17 | 7.1 | 2 | pembrolizumab 200 mg q3w | 6.5 | false | MSS | 2026-03-15T05:35:59.945082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466060 | REC_0012328 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 17.8 | 64 | male | 0 | 21 | 5.4 | 1 | osimertinib 80 mg daily | 30.4 | false | MSI-H | 2026-03-15T05:35:59.945316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513448 | REC_0012329 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7 | 73 | female | 2 | 52 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:59.945554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752490 | REC_0012330 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 10.7 | 76 | male | 1 | 9 | 4.8 | 2 | osimertinib 80 mg daily | 18.4 | true | MSI-H | 2026-03-15T05:35:59.945791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212512 | REC_0012331 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8.4 | 69 | female | 0 | 7 | 6.3 | 6 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:59.946024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268827 | REC_0012332 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 13 | 14.5 | 66 | female | 0 | 9 | 4 | 7 | alectinib 600 mg BID | 11.6 | true | MSI-H | 2026-03-15T05:35:59.946255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112527 | REC_0012333 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 25 | 12.3 | 63 | female | 0 | 24 | 5.2 | 0 | sotorasib 960 mg daily | 52 | true | MSS | 2026-03-15T05:35:59.946490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276777 | REC_0012334 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.4 | 63 | female | 1 | 25 | 4.6 | 5 | alectinib 600 mg BID | 10.4 | true | MSS | 2026-03-15T05:35:59.946723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268995 | REC_0012335 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 4.2 | 68 | male | 1 | 36 | 5.1 | 8 | carboplatin + paclitaxel + pembrolizumab | 17.9 | false | MSS | 2026-03-15T05:35:59.946954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935567 | REC_0012336 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.9 | 73 | female | 0 | 11 | 6.2 | 7 | sotorasib 960 mg daily | 11 | false | MSS | 2026-03-15T05:35:59.947183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670744 | REC_0012337 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8.8 | 64 | female | 0 | 10 | 5.7 | 4 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:59.947415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445914 | REC_0012338 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.5 | 53 | female | 0 | 19 | 5.3 | 2 | sotorasib 960 mg daily | 22.5 | true | MSS | 2026-03-15T05:35:59.947692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815533 | REC_0012339 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 12.8 | 71 | female | 1 | 9 | 7 | 6 | alectinib 600 mg BID | 7.5 | false | MSS | 2026-03-15T05:35:59.947927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208935 | REC_0012340 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 11.1 | 75 | male | 0 | 14 | 4.2 | 1 | sotorasib 960 mg daily | 9.7 | true | MSS | 2026-03-15T05:35:59.948213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911433 | REC_0012341 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 16.2 | 60 | female | 0 | 15 | 4.7 | 3 | sotorasib 960 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:59.948468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787886 | REC_0012342 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 15.3 | 64 | male | 0 | 13 | 4.5 | 6 | entrectinib 600 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:59.948713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170565 | REC_0012343 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 16.3 | 60 | female | 1 | 19 | 5.6 | 7 | entrectinib 600 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:59.948960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598171 | REC_0012344 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 17 | 81 | female | 1 | 13 | 4 | 1 | sotorasib 960 mg daily | 20 | false | MSI-H | 2026-03-15T05:35:59.949216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524661 | REC_0012345 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 11.9 | 77 | male | 1 | 8 | 5.6 | 8 | alectinib 600 mg BID | 6.2 | false | MSI-H | 2026-03-15T05:35:59.949463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310379 | REC_0012346 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 25 | 20.1 | 56 | female | 1 | 13 | 6.2 | 0 | sotorasib 960 mg daily | 48.3 | true | MSS | 2026-03-15T05:35:59.949707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677990 | REC_0012347 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 6.7 | 47 | female | 0 | 16 | 5.2 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.949946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750316 | REC_0012348 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10 | 79 | female | 3 | 19 | 5.6 | 5 | entrectinib 600 mg daily | 4.1 | true | MSI-H | 2026-03-15T05:35:59.950184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535726 | REC_0012349 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 10.8 | 64 | female | 0 | 14 | 5.9 | 4 | entrectinib 600 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:35:59.950423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756779 | REC_0012350 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 15 | 5.7 | 74 | female | 1 | 51 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.1 | false | MSS | 2026-03-15T05:35:59.950662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795136 | REC_0012351 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.4 | 73 | female | 2 | 17 | 6.8 | 1 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:35:59.951056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976704 | REC_0012352 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7.9 | 63 | male | 0 | 53 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.4 | true | MSS | 2026-03-15T05:35:59.951355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181360 | REC_0012353 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 8.4 | 74 | female | 1 | 8 | 9.1 | 1 | entrectinib 600 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:59.951650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387569 | REC_0012354 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 9 | 68 | female | 0 | 15 | 4.1 | 2 | entrectinib 600 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:59.951943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405524 | REC_0012355 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 4.4 | 55 | male | 1 | 54 | 6.4 | 7 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:35:59.952320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876459 | REC_0012356 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.8 | 66 | male | 0 | 14 | 6.4 | 4 | entrectinib 600 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:59.952662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444076 | REC_0012357 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.8 | 80 | male | 2 | 12 | 5.8 | 2 | osimertinib 80 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:35:59.952981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139904 | REC_0012358 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 9.3 | 79 | female | 3 | 9 | 4.7 | 1 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:59.953288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253456 | REC_0012359 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.7 | 78 | female | 2 | 19 | 3.1 | 5 | alectinib 600 mg BID | 10.4 | true | MSI-H | 2026-03-15T05:35:59.953590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115161 | REC_0012360 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 10.4 | 62 | male | 0 | 16 | 6.4 | 2 | alectinib 600 mg BID | 19.9 | true | MSI-H | 2026-03-15T05:35:59.953862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689803 | REC_0012361 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.2 | 78 | female | 2 | 20 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.4 | false | MSS | 2026-03-15T05:35:59.954119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746542 | REC_0012362 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.7 | 69 | female | 1 | 20 | 6 | 5 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:59.954404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739834 | REC_0012363 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 11.3 | 77 | female | 2 | 20 | 6.8 | 1 | alectinib 600 mg BID | 19.9 | true | MSS | 2026-03-15T05:35:59.954655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821924 | REC_0012364 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 18.9 | 57 | female | 0 | 17 | 6.1 | 2 | entrectinib 600 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:59.955034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494899 | REC_0012365 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.4 | 86 | female | 1 | 41 | 4.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:35:59.955315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888021 | REC_0012366 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 22.5 | 69 | female | 0 | 11 | 4.6 | 5 | pembrolizumab 200 mg q3w | 13.4 | false | MSS | 2026-03-15T05:35:59.955573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593946 | REC_0012367 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 16.6 | 49 | male | 0 | 13 | 5.2 | 2 | pembrolizumab 200 mg q3w | 6.8 | true | MSS | 2026-03-15T05:35:59.955832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656215 | REC_0012368 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 6.3 | 73 | male | 1 | 1 | 4.6 | 0 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.956151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751236 | REC_0012369 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 3.4 | 64 | female | 0 | 10 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.1 | false | MSS | 2026-03-15T05:35:59.956429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389625 | REC_0012370 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 15.6 | 68 | female | 0 | 19 | 4.8 | 4 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:59.956698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324191 | REC_0012371 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 16.1 | 65 | male | 1 | 11 | 5.8 | 8 | sotorasib 960 mg daily | 14 | true | MSI-H | 2026-03-15T05:35:59.956963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854111 | REC_0012372 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 2.5 | 71 | female | 1 | 49 | 5.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.6 | true | MSS | 2026-03-15T05:35:59.957231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674159 | REC_0012373 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 14.4 | 59 | female | 0 | 9 | 6.2 | 6 | pembrolizumab 200 mg q3w | 7.8 | false | MSI-H | 2026-03-15T05:35:59.957495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487025 | REC_0012374 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 6.6 | 70 | male | 2 | 1 | 5.2 | 2 | osimertinib 80 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:59.957748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896357 | REC_0012375 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 15.9 | 61 | male | 1 | 29 | 4.8 | 5 | sotorasib 960 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:59.958006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693307 | REC_0012376 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 5.5 | 74 | female | 2 | 8 | 6.1 | 5 | osimertinib 80 mg daily | 15.1 | true | MSS | 2026-03-15T05:35:59.958252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376692 | REC_0012377 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 14.9 | 75 | female | 2 | 15 | 4.4 | 4 | pembrolizumab 200 mg q3w | 15.6 | false | MSS | 2026-03-15T05:35:59.958644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713561 | REC_0012378 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 5.8 | 68 | female | 1 | 15 | 5.3 | 5 | sotorasib 960 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:59.958901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434735 | REC_0012379 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 7.5 | 73 | female | 2 | 67 | 4.5 | 2 | pembrolizumab 200 mg q3w | 28.2 | false | MSS | 2026-03-15T05:35:59.959152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660078 | REC_0012380 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.9 | 52 | female | 0 | 20 | 4.3 | 6 | alectinib 600 mg BID | 10.1 | false | MSS | 2026-03-15T05:35:59.959409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987211 | REC_0012381 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 14.4 | 53 | female | 0 | 4 | 5.8 | 5 | alectinib 600 mg BID | 12.9 | true | MSI-H | 2026-03-15T05:35:59.959652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539412 | REC_0012382 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.6 | 75 | female | 1 | 37 | 5 | 7 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:35:59.959887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807715 | REC_0012383 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 11.5 | 69 | female | 1 | 18 | 6.5 | 1 | sotorasib 960 mg daily | 17.3 | false | MSS | 2026-03-15T05:35:59.960253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176044 | REC_0012384 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 6.4 | 66 | female | 1 | 13 | 4.3 | 1 | sotorasib 960 mg daily | 19.6 | true | MSS | 2026-03-15T05:35:59.960511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849240 | REC_0012385 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13.8 | 68 | female | 0 | 6 | 4.8 | 2 | alectinib 600 mg BID | 13.9 | true | MSS | 2026-03-15T05:35:59.960752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876726 | REC_0012386 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 11.4 | 65 | female | 0 | 20 | 5.4 | 0 | entrectinib 600 mg daily | 45.5 | false | MSI-H | 2026-03-15T05:35:59.960994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559512 | REC_0012387 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.9 | 75 | female | 1 | 23 | 5.3 | 4 | alectinib 600 mg BID | 7.6 | false | MSI-H | 2026-03-15T05:35:59.961228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470001 | REC_0012388 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 9.4 | 68 | female | 0 | 10 | 7.5 | 5 | osimertinib 80 mg daily | 9 | false | MSS | 2026-03-15T05:35:59.961457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664555 | REC_0012389 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 6.3 | 67 | female | 1 | 4 | 6.1 | 1 | alectinib 600 mg BID | 18.6 | false | MSS | 2026-03-15T05:35:59.961692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179247 | REC_0012390 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.7 | 63 | female | 0 | 17 | 4.6 | 7 | osimertinib 80 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:59.962043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123659 | REC_0012391 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11 | 75 | female | 1 | 17 | 5.1 | 6 | osimertinib 80 mg daily | 16.4 | true | MSI-H | 2026-03-15T05:35:59.962314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335632 | REC_0012392 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 14.7 | 72 | female | 0 | 16 | 3.6 | 2 | osimertinib 80 mg daily | 19.3 | true | MSI-H | 2026-03-15T05:35:59.962556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651629 | REC_0012393 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 8.7 | 61 | female | 0 | 17 | 7 | 3 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:59.962793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645514 | REC_0012394 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.6 | 47 | female | 0 | 62 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.4 | false | MSS | 2026-03-15T05:35:59.963025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355500 | REC_0012395 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.2 | 57 | female | 1 | 16 | 4.3 | 1 | alectinib 600 mg BID | 17.4 | false | MSI-H | 2026-03-15T05:35:59.963264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304260 | REC_0012396 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.5 | 59 | male | 0 | 19 | 5.3 | 6 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:59.963497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371073 | REC_0012397 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11 | 60 | female | 0 | 12 | 5.1 | 8 | sotorasib 960 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:59.963733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840959 | REC_0012398 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 11.4 | 67 | female | 0 | 17 | 4.5 | 1 | osimertinib 80 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:35:59.963965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381830 | REC_0012399 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.8 | 57 | male | 1 | 41 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 34.9 | true | MSS | 2026-03-15T05:35:59.964249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563896 | REC_0012400 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.2 | 66 | female | 0 | 11 | 3.5 | 6 | sotorasib 960 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:59.964489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.